April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Comparing Morbidity Rates in Retinopathy of Prematurity Treated with Either Intravitreal Bevacizumab or Conventional Laser Therapy
Author Affiliations & Notes
  • Stephen M Huddleston
    Ophthalmology, University of Tennessee, Memphis, TN
  • Julie Calderwood
    Ophthalmology, University of Tennessee, Memphis, TN
  • Mary E Hoehn
    Ophthalmology, University of Tennessee, Memphis, TN
  • Footnotes
    Commercial Relationships Stephen Huddleston, None; Julie Calderwood, None; Mary Hoehn, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 6357. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Stephen M Huddleston, Julie Calderwood, Mary E Hoehn; Comparing Morbidity Rates in Retinopathy of Prematurity Treated with Either Intravitreal Bevacizumab or Conventional Laser Therapy. Invest. Ophthalmol. Vis. Sci. 2014;55(13):6357.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Controversy still exists regarding the safety profile of anti-vascular endothelial growth factor agents versus traditional laser therapy in the treatment of retinopathy of prematurity. With this in mind, we designed a study to compare morbidity markers between these two treatment groups.

Methods: The last ten patients treated with laser therapy and the last ten patients treated with bevacizumab for retinopathy of prematurity at our institution were identified, and their charts were retrospectively analyzed. Patients were excluded if they had received both modalities of treatment. Our morbidity markers included: number of days that ventilator support was required following treatment, length of hospital stay following treatment, and mortality.

Results: Our preliminary results indicate that length of hospital stay following therapy was longer in patients receiving laser treatment compared to those receiving intravitreal bevacizumab (80 days versus 61 days). Two patients in the laser group required prolonged ventilator support following treatment compared to no patients in the bevacizumab group. Mortality was found to be equal in both groups.

Conclusions: Use of intravitreal bevacizumab for vision threatening retinopathy of prematurity did not result in increased length of hospital stay nor prolonged ventilator support following treatment when compared to traditional laser therapy, and mortality was found to be equal between our two treatment groups.

Keywords: 706 retinopathy of prematurity • 748 vascular endothelial growth factor  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×